|
AP646A
(en)
*
|
1995-03-27 |
1998-04-27 |
Sanofi Synthelabo |
Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
|
|
WO1998014169A1
(en)
*
|
1996-09-30 |
1998-04-09 |
Brigham & Women's Hospital |
Methods and compounds for treatment of abnormal uterine bleeding
|
|
DE69824750T2
(de)
*
|
1997-10-31 |
2005-07-07 |
Children's Medical Center Corp., Boston |
Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
|
|
NZ511408A
(en)
*
|
1998-10-09 |
2004-04-30 |
Licentia Ltd |
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
|
|
US7141607B1
(en)
*
|
2000-03-10 |
2006-11-28 |
Insite Vision Incorporated |
Methods and compositions for treating and inhibiting retinal neovascularization
|
|
JPWO2004022082A1
(ja)
*
|
2002-09-04 |
2005-12-22 |
株式会社プロテイン・エクスプレス |
胚着床制御剤
|
|
WO2004103159A2
(en)
*
|
2003-05-14 |
2004-12-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for modulating endometrium
|
|
NZ545188A
(en)
*
|
2003-07-14 |
2008-12-24 |
Fusion Sport Internat Pty Ltd |
Sports training and testing methods, apparatus and system
|
|
US7524811B2
(en)
*
|
2003-08-29 |
2009-04-28 |
Children's Medical Center Corporation |
Anti-angiogenic peptides from the N-terminus of endostatin
|
|
DE602004015142D1
(de)
*
|
2003-08-29 |
2008-08-28 |
Childrens Medical Center |
Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
|
|
WO2009139915A2
(en)
|
2008-05-15 |
2009-11-19 |
The University Of North Carolina At Chapel Hill |
Novel targets for regulation of angiogenesis
|
|
EP2140860A1
(en)
|
2008-07-03 |
2010-01-06 |
Bayer Schering Pharma Oy |
An improved method of contraception
|
|
EP2317845A4
(en)
*
|
2008-07-18 |
2011-11-09 |
Zafgen Inc |
METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
|
|
US20100159506A1
(en)
*
|
2008-07-25 |
2010-06-24 |
Cellscape Corporation |
Methods and systems for genetic analysis of fetal nucleated red blood cells
|
|
US8642650B2
(en)
|
2008-12-04 |
2014-02-04 |
Zafgen, Inc. |
Methods of treating an overweight or obese subject
|
|
WO2010065877A2
(en)
|
2008-12-04 |
2010-06-10 |
Zafgen Corporation |
Methods of treating an overweight or obese subject
|
|
WO2013055385A2
(en)
|
2011-10-03 |
2013-04-18 |
Zafgen Corporation |
Methods of treating age related disorders
|
|
CN102639494B
(zh)
|
2009-10-09 |
2016-11-09 |
扎夫根公司 |
砜化合物及其制备和使用方法
|
|
WO2011085198A1
(en)
|
2010-01-08 |
2011-07-14 |
Zafgen Corporation |
Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
|
|
WO2011085201A1
(en)
|
2010-01-08 |
2011-07-14 |
Zafgen Corporation |
Fumagillol type compounds and methods of making and using same
|
|
RU2427325C1
(ru)
*
|
2010-01-29 |
2011-08-27 |
Государственное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО АГМА Росздрава) |
Способ оценки эффективности лечения хронической плацентарной недостаточности в эксперименте
|
|
US8774488B2
(en)
|
2010-03-11 |
2014-07-08 |
Cellscape Corporation |
Method and device for identification of nucleated red blood cells from a maternal blood sample
|
|
WO2011127304A2
(en)
|
2010-04-07 |
2011-10-13 |
Zafgen Corporation |
Methods of treating an overweight subject
|
|
CA2796744A1
(en)
|
2010-04-17 |
2011-10-20 |
Bayer Healthcare Llc |
Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
JP2013531067A
(ja)
|
2010-07-19 |
2013-08-01 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
|
|
WO2012012642A1
(en)
|
2010-07-22 |
2012-01-26 |
Zafgen Corporation |
Tricyclic compounds and methds of making and using same
|
|
PH12013500934A1
(en)
|
2010-11-09 |
2022-10-24 |
Zafgen Inc |
Crystalline solids of a metap-2 inhibitor and methods of making and using same
|
|
AU2011336785A1
(en)
|
2010-11-29 |
2013-06-20 |
Zafgen, Inc |
Treatment of obesity using non-daily administration of 6-0-(4 - dimethylaminoethoxy) cinnamoyl fumagillol
|
|
CN103402989B
(zh)
|
2011-01-26 |
2016-04-06 |
扎夫根股份有限公司 |
四唑化合物及其制备和使用方法
|
|
AU2012225531B2
(en)
|
2011-03-08 |
2017-03-30 |
Zafgen, Inc |
Oxaspiro (2.5) octane derivatives and analogs
|
|
EP2705035B1
(en)
|
2011-05-06 |
2016-12-14 |
Zafgen, Inc. |
Tricyclic pyrazole sulfonamide compounds and methods of making and using same
|
|
CN103748094B
(zh)
|
2011-05-06 |
2016-06-29 |
扎夫根股份有限公司 |
三环磺酰胺化合物及其制备和使用方法
|
|
CA2835261C
(en)
|
2011-05-06 |
2019-06-04 |
Zafgen, Inc. |
Partially saturated tricyclic compounds and methods of making and using same
|
|
EP2804866B1
(en)
|
2012-01-18 |
2016-11-16 |
Zafgen, Inc. |
Tricyclic sulfonamide compounds and methods of making and using same
|
|
EP2804856B1
(en)
|
2012-01-18 |
2017-03-15 |
Zafgen, Inc. |
Tricyclic sulfone compounds and methods of making and using same
|
|
US9260419B2
(en)
|
2012-05-07 |
2016-02-16 |
Zafgen, Inc. |
Polymorphic salt of a metap-2 inhibitor and methods of making and using same
|
|
MX2014013599A
(es)
|
2012-05-08 |
2015-05-11 |
Zafgen Inc |
Tratamiento de la obesidad hipotalamica con inhibidores de metap2.
|
|
US9573918B2
(en)
|
2012-05-09 |
2017-02-21 |
Zafgen, Inc. |
Fumigillol compounds and methods of making and using same
|
|
EP2917197B1
(en)
|
2012-11-05 |
2019-06-05 |
Zafgen, Inc. |
Tricyclic compounds and methods of making and using same
|
|
EP2925737B1
(en)
|
2012-11-05 |
2017-06-14 |
Zafgen, Inc. |
Tricyclic compounds for use in the treatment and/or control of obesity
|
|
CA2890343A1
(en)
|
2012-11-05 |
2014-05-08 |
Zafgen, Inc. |
Tricyclic compounds useful in the treatment of liver disorders
|
|
EP2968250B1
(en)
|
2013-03-14 |
2019-06-19 |
Zafgen, Inc. |
Methods of treating renal disease and other disorders
|
|
CN106432255A
(zh)
|
2015-08-11 |
2017-02-22 |
扎夫根公司 |
烟曲霉素醇螺环化合物和制备和使用其的方法
|
|
AR105671A1
(es)
|
2015-08-11 |
2017-10-25 |
Zafgen Inc |
Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
|